Translate page

Michael Mauro


Professor Michael Mauro
Leader of the Myeloproliferative Neoplams Program at the Memorial Sloan Kettering Cancer Centre / Professor of Clinical Medicine at the Weill Cornell Medical College, New York (USA)

Overview of significant clinical aspects presented during the meeting, including:

  • 00:51 ASCIMINIB
    • ASCEND Study
    • ASC4More Study
  • 04:49 Olverembatinib
    • Olverembatinib in patients with T315I mutation
    • Olverembatinib in resistant CML
  • 08:32 Vodobatinib phase 1 Study
  • 11:35 Dasatinib, PEG-INF, Ponatinib
    • Long-term low-dose Dasatinib frontline in CML
    • ENDURE Study: PEG-INF after discontinuation
    • OPTIC Trial: Optimization of Ponatinib in different doses
  • 18:28 Non-ABL Myeloid Mutations
  • 22:16 TFR, Race/ethnicity, AP-CML and BC-CML
    • TFR-PRO Observational Study
    • Survival by race/ethnicity
    • 2nd generation TKI vs Imatinib in AP-CML
    • BC-CML Registry

If you have any questions or comments to the speaker, please email